Valeo Pharma
  • About Us
    • Overview
    • Board of Directors
    • Executive Team
  • Product Portfolio
    • Respiratory / Allergy
    • Ophthalmology
    • Specialty Products
    • Neurology
    • Oncology
  • Partnering
  • Investors
    • Investor Relations
    • Stock information
    • Corporate Presentation
    • Financial Reports
    • Newsroom
    • Webcasts / Events
    • SEDAR documents
  • Careers
  • Contact
  • Français
Select Page
VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022

VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022

by Fred Dumais | Jan 30, 2023 | News Release

Record quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21 Record revenues in 2022 of $27.7 million, up 105% over 2021 Record revenues forecasted in Q1-23 Creation of Ophthalmology Business Unit following the addition of XIIDRA® and SIMBRINZA®, expansion...
VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS

VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS

by Fred Dumais | Jan 26, 2023 | News Release

In the final analysis of the Phase 3 cinical study conducted by Veru Inc., sabizabulin showed a 51.6% reduction in deaths compared to placebo in hospitalized adult patients with moderate to severe COVID-19 who are at high risk for ARDS Sabizabulin also showed a...
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST     

VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST     

by Fred Dumais | Jan 25, 2023 | News Release

MONTREAL, QUEBEC , January 25, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended...
Next Entries »

Recent News

  • VALEO PHARMA ANTICIPE DES REVENUS RECORDS POUR LE DEUXIÈME TRIMESTRE DE 2023  May 25, 2023
  • VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023  May 25, 2023
  • VALEO PHARMA ANNONCE LES RÉSULTATS DE L’ASSEMBLÉE ANNUELLE DES ACTIONNAIRES ET LES NOMINATIONS AUX COMITÉS April 28, 2023
  • VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS April 28, 2023

Stay in the loop

I consent to receive news, updates and special offers from Valeo Pharma and it’s affiliates.

Contact us

1-855-694-0151
[email protected]
16667 Hymus Blvd.
Kirkland, QC H9H 4R9

  • About Us
  • Board of Directors
  • Management Team
  • Careers
  • Our Products
  • Business Development
  • Investors Overview
  • Newsroom
  • Stock Information
  • Financial Reports
  • Contact Us
  • Français

© 2022 Valeo Pharma. All rights reserved.

Speak to a professional

I want to speak to:

8 + 6 =